The FDA approved lurbinectedin and atezolizumab for first-line maintenance in ES-SCLC, showing improved progression-free and overall survival. The IMforte trial demonstrated a 46% reduction in disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback